TABLE 2.

The wound edge velocity changes under drug treatment by microtubule-destabilizing drugs.

Cell line	Nocodazole treatment
	10 nM	30 nM	100 nM	300 nM	1,000 nM	3,000 nM
3T3	86.28**	99.41 ns	83.91**	42.61**	15.12**	−4.56**
HPF	85.91 ns	100.03 ns	117.93*	43.11**	36.90**	35.20**
HaCaT	86.52**	71.42**	74.37**	44.75**	52.30**	53.75**
A549	102.20 ns	108.43*	93.81 ns	53.90**	46.72**	4.50**
HeLa	115.37*	105.44 ns	95.15 ns	69.35**	53.97**	57.37**
PC-3	82.36**	73.19*	60.96**	43.44**	50.39**	47.48**
MCF-7	92.71 ns	99.90 ns	106.05 ns	102.10 ns	89.43 ns	71.17**
MCF DOX	86.71**	77.31**	91.74ns	90.49**	89.54 ns	83.74**
HT1080	N/A	111.76*	79.67*	71.22*	73.73*	72.24*
U2OS	100.15 ns	111.48 ns	106.24 ns	78.82**	52.80**	41.09**
Cell line	Taxol treatment
	10 nM	30 nM	100 nM	300 nM	1,000 nM	3,000 nM
3T3	96.37ns	104.82 ns	73.65**	59.07**	27.44**	−2.37**
HPF	35.69**	36.81**	18.57**	21.13**	5.09**	16.65**
HaCaT	73.07**	36.35**	63.99**	58.89**	36.19**	28.62**
A549	118.79**	117.05**	107.39*	97.53 ns	93.40*	52.59**
HeLa	77.97**	70.31**	62.39**	49.25**	51.06**	40.22**
PC-3	48.77**	38.58**	55.26**	52.61**	52.95**	59.62**
MCF-7	94.65ns	71.62**	84.73**	58.07**	55.05**	49.13**
MCF DOX	98.00ns	84.80**	81.31**	86.56**	77.16**	68.89**
HT1080	N/A	73.27**	48.45**	46.78**	36.73**	45.21**
U2OS	74.37**	73.66**	66.87**	55.31**	53.77**	43.68**
Cell line	Vinorelbine treatment
	10 nM	30 nM	100 nM	300 nM	1,000 nM	3,000 nM
3T3	77.22**	74.84**	44.27**	36.45**	11.29**	−0.09**
HPF	100.72 ns	110.96 ns	75.56**	63.19**	30.95**	26.92**
HaCaT	52.88**	43.36**	35.23**	54.81**	25.75**	26.30**
A549	109.16 *	112.96 *	107.84 *	76.25**	63.70**	6.93**
HeLa	101.28 ns	94.76 ns	74.71**	57.92**	60.00**	58.26**
PC-3	57.62**	42.69**	45.17**	36.88**	48.68**	44.88**
MCF-7	27.16**	39.47**	44.55**	34.40**	13.08**	−10.35**
MCF DOX	40.27**	58.52**	66.06**	51.01**	19.40**	−15.35**
HT1080	N/A	63.43**	66.93**	70.28**	71.96**	36.23**
U2OS	N/A	96.52**	114.96**	108.37*	69.57**	52.48**

Ns, non-significant. *Significant, p < 0.05. **Highly significant, p < 0.001 by Mann–Whitney U test.